A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Study sponsor: Celldex Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-28Actual
Enrollment · participants208Actual
Source updated2025-03-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.